Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#1251 Biodistribution and Radiation Dosimetry of a Novel 18F-Fluoroethyl Triazole [Tyr3] Octreotate Analogue for PET Imaging Patients with Advanced Neuroendocrine Tumours.

Introduction: Despite advances, detection and quantification of NET activity by imaging remains a challenge.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: DUBASH S

Authors: Dubash S, Keat N, Mapelli P, Twyman F, Carroll L,

Keywords: PET,

#1156 Characterisation, Measurement and Biodistribution of an Improved Formulation of [Lu-177]-Octreotate

Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Bailey D

Authors: Bailey D, Willowson K, Hennessy T, Schembri G, Snowdon G,

Keywords: lutetium, dosimetry, biodistribution, effective dose,

#1105 Pre-PRRT Uptake on 68Ga-DOTATOC Predicts Good Prognosis in Neuroendocrine Tumors Patients

Introduction: There is a growing need to identify PRRT-responders on an early time point during therapy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Van Binnebeek S

Authors: Van Binnebeek S, Vanbilloen B, Baete K, Bogaerts K, Koole M,

Keywords: PET, response, PRRT,

#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC

Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Mottaghy F,

Keywords: PRRT, 90y-DOTATOC, dosimetry, 111in-octreotide, amino acids,